J&J beats street with profits, sales

Johnson & Johnson's $15.4 billion in second-quarter revenues beat analyst forecasts as Remicade sales came on strong, partly making up for patent expirations on the antipsychotic Risperdal and the seizure med Topamax. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.